SCHEDULE: Two Seas Capital Discloses 6.8% Stake in Nektar

Two Seas Capital LP has filed a Schedule 13G reporting a 6.8% beneficial ownership stake in Nektar Therapeutics.

Summary

• Two Seas Capital LP, Two Seas Capital GP LLC, and Sina Toussi have collectively reported beneficial ownership of 1,959,178 shares of Nektar Therapeutics common stock.
• This holding represents 6.8% of the company's total outstanding common stock based on 28,687,963 shares outstanding as of March 11, 2026.
• The reporting persons maintain sole voting and dispositive power over the shares held by the Two Seas Global (Master) Fund LP.
• The filing is made as a passive investment, certifying that the shares were not acquired for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral regulatory disclosure reflecting standard institutional portfolio management activity.

Positives

• Institutional investor confidence indicated by a significant 6.8% equity position.
• The filing confirms the investment is held in the ordinary course of business, suggesting a long-term investment strategy rather than activist intervention.

Negatives

• None identified in this regulatory disclosure.

Risks

• Market volatility associated with Nektar Therapeutics' stock price.
• Reliance on the accuracy of the issuer's reported outstanding share count for percentage calculations.

Future Outlook

The filing does not provide forward-looking guidance on the issuer's business operations, as it is a standard ownership disclosure.

Industry Context

StockSavvy.ai notes that institutional filings of this nature are standard in the biotechnology sector, where specialized investment firms often take significant positions in companies undergoing clinical trials or strategic pivots.

Comparison to Industry Standards

• The 6.8% stake is consistent with typical institutional holdings for mid-cap biotech firms.
• The use of a Schedule 13G (rather than 13D) is the industry standard for passive investors who do not intend to influence corporate governance.

Stakeholder Impact

• Shareholders may view the entry of an institutional investor as a sign of market validation for the company's current valuation.

Next Steps

• The reporting persons are required to file amendments if there are material changes in the percentage of ownership.

Key Dates

Keywords

Nektar Therapeutics, Schedule 13G, Two Seas Capital, Institutional Ownership, Equity Disclosure, Biotech Investment